Dr. Gentzler delivers an informative and comprehensive update on the Experimental Therapeutics Clinical Trials Network (ETCTN), emphasizing its central role in the early-phase drug development pipeline supported by the National Cancer Institute (NCI).
Dr. Mixon begins by defining lymphedema as a chronic, progressive condition often resulting from cancer treatment. A key focus is on identifying patients at high risk, including those undergoing lymph node dissection or radiation. She underscores the importance of risk stratification and proactive intervention to prevent progression to irreversible stages.
Dr. Yao highlights that approximately 2 million older adults in the US are permanently homebound, with cancer among the leading diagnoses, and many more experience frequent periods of functional decline or immobility. These patients face significant disparities in access to care, particularly racial and ethnic minorities who are more likely to die at home without adequate support.
Dr. Godley emphasizes the increasing recognition of germline predisposition in hematopoietic malignancies, challenging traditional assumptions that these genetic factors are rare. The talk includes a short Q&A discussion at the end.
Dr. Zimmer provides an in-depth exploration of brain metastases in breast cancer, emphasizing the challenges in management and evolving treatment strategies, outlining the clinical complexities associated with HER2-positive, triple-negative, and hormone receptor-positive breast cancers and their distinct metastatic patterns and treatment responses.
Dr. Jackson provides a detailed overview of current therapeutic options for COVID-19, distinguishing between outpatient and inpatient care strategies. Dr. Jackson emphasizes early treatment within the first five days of symptoms. Nirmatrelvir/ritonavir (Paxlovid) is highlighted as the preferred option due to its robust efficacy in preventing hospitalization and death. Remdesivir, administered over three days intravenously, is considered a suitable alternative for those unable to take Paxlovid.
The goal of this educational program is to improve the treatment of patients with multiple myeloma (MM) and non-hodgkin lymphoma (NHL) through the dissemination of information about stem cell transplantation and mobilization for autologous hematopoietic cell transplantation. The data for stem cell transplantation in MM is rapidly changing. The techniques of mobilization are still evolving.